Compare · AZN vs UPB
AZN vs UPB
Side-by-side comparison of AstraZeneca PLC (AZN) and Upstream Bio Inc. (UPB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and UPB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 1400.4x UPB ($184.6M).
- Over the past year, AZN is up 95.4% and UPB is down 86.9% - AZN leads by 182.3 points.
- AZN has hit the wire 18 times in the past 4 weeks while UPB has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 10 for UPB).
- Company
- AstraZeneca PLC
- Upstream Bio Inc.
- Price
- $165.42-0.74%
- $2.75-18.18%
- Market cap
- $258.47B
- $184.6M
- 1M return
- -0.43%
- -48.45%
- 1Y return
- +95.37%
- -86.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2024
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 10
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest UPB
- General Counsel Ambrose Allison sold $2,663 worth of shares (485 units at $5.49), decreasing direct ownership by 3% to 15,563 units (SEC Form 4) to satisfy withholding tax
- CFO and COO Gray Michael sold $4,683 worth of shares (853 units at $5.49), decreasing direct ownership by 3% to 27,942 units (SEC Form 4) to satisfy withholding obligation
- Chief Medical Officer Deykin Aaron sold $4,914 worth of shares (895 units at $5.49), decreasing direct ownership by 3% to 32,302 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Houghton Adam sold $3,843 worth of shares (700 units at $5.49), decreasing direct ownership by 3% to 22,901 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Sutherland Everett Rand sold $11,502 worth of shares (2,095 units at $5.49), decreasing direct ownership by 3% to 68,717 units (SEC Form 4) (withholding obligation)
- Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
- Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.
- SEC Form 10-Q filed by Upstream Bio Inc.